As of May, 8 The EPS for OPKO Health, Inc. (OPK) Expected At $-0.14

April 16, 2018 - By Robert Reynolds

During Q4 2017 the big money sentiment decreased to 0.84. That’s change of 0.30, from 2017Q3’s 1.14. 32 investors sold all, 60 reduced holdings as OPKO Health, Inc. ratio dived. 53 increased positions while 24 funds acquired positions. Funds hold 119.15 million shares thus 0.51% less from 2017Q3’s 119.76 million shares.
Voya Investment Mgmt Ltd Liability Corp holds 92,943 shs. Pub Employees Retirement Association Of Colorado reported 0% of its capital in OPKO Health, Inc. (NASDAQ:OPK). Schwab Charles Inv Mgmt, a California-based fund reported 1.56 million shs. Cornerstone Cap Mgmt stated it has 0.07% of its capital in OPKO Health, Inc. (NASDAQ:OPK). Howard Capital Management has invested 0.01% in OPKO Health, Inc. (NASDAQ:OPK). Pennsylvania-based Susquehanna Intll Grp Inc Ltd Liability Partnership has invested 0% in OPKO Health, Inc. (NASDAQ:OPK). Ancora Advsrs Limited Liability Corp holds 0.01% or 40,280 shs. Meeder Asset Mgmt has invested 0% in OPKO Health, Inc. (NASDAQ:OPK). 46,820 were reported by Aperio Grp Lc. Shufro Rose Lc reported 0.09% stake. Invesco Ltd stated it has 0% of its capital in OPKO Health, Inc. (NASDAQ:OPK). Oracle Inv Management accumulated 3.83M shs. Hightower Limited Liability Corp has 0% invested in OPKO Health, Inc. (NASDAQ:OPK) for 90,079 shs. Moreover, Proshare Llc has 0.01% invested in OPKO Health, Inc. (NASDAQ:OPK). Hartline Invest Corporation holds 0.03% of its capital in OPKO Health, Inc. (NASDAQ:OPK) for 20,634 shs.

OPKO Health, Inc. registered $9.09 million net activity with 35 insider purchases and 0 insider sales since January 22, 2018. Rubin Steven D also bought $19,500 worth of OPKO Health, Inc. (NASDAQ:OPK) shs. On Tuesday, March 13 Logal Adam bought $7,011 worth of OPKO Health, Inc. (NASDAQ:OPK). Shares for $31,600 were bought by Fishel Robert Scott on Friday, April 6.

On May, 8 WallStreet awaited OPKO Health, Inc. (NASDAQ:OPK)’s earnings report, Zacks reports. Last year’s earnings per share was $-0.06, while now analysts expect change of 133.33 % down from current $-0.14 earnings per share. After $-0.12 earnings per share was revealed last quarter, analysts now see negative EPS growth of 16.67 % for OPKO Health, Inc.. Its shares touched $3.02 on during the last trading session after 1.00% change.Currently OPKO Health, Inc. is downtrending after 60.81% change in last April 17, 2017. OPK has 2.61 million shares volume. OPK underperformed the S&P 500 by 72.36%.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico.The company has $1.69 billion market cap. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.Last it reported negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

OPKO Health, Inc. (NASDAQ:OPK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.